Literature DB >> 31777386

Quantifying the benefit of non-small-cell lung cancer immunotherapy - Authors' reply.

Tony S K Mok1, Jin Zhang2, Gilberto Lopes3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31777386     DOI： 10.1016/S0140-6736(19)32605-4

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  2 in total

1.  Clinical outcomes and predictive value of programmed cell death-ligand 1 expression in response to anti-programmed cell death 1/ligand 1 antibodies in non-small cell lung cancer patients with performance status 2 or greater.

Authors:  Takayuki Jodai; Koichi Saruwatari; Tokunori Ikeda; Eiji Moriyama; Kosuke Kashiwabara; Naoki Shingu; Kazuhiro Iyonaga; Megumi Inaba; Yusuke Ajishi; Chiharu Honda; Susumu Hirosako; Hirotaka Maruyama; Yosuke Kakiuchi; Hirofumi Eida; Yusuke Tomita; Sho Saeki; Hidenori Ichiyasu; Takuro Sakagami
Journal:  Int J Clin Oncol       Date:  2020-09-23       Impact factor: 3.402

2.  Impact of p16 Status and Anatomical Site in Anti-PD-1 Immunotherapy-Treated Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Patients.

Authors:  Kate Clancy; Chelsea S Hamill; W Quinn O'Neill; Brandon Vu; Jason Thuener; Shanying Gui; Shawn Li; Nicole Fowler; Rod Rezaee; Pierre Lavertu; Jay Wasman; Monaliben Patel; Hira Shaikh; Eric Vick; Anant Madabhushi; Trisha M Wise-Draper; Kyunghee Burkitt; Theodoros N Teknos; Quintin Pan
Journal:  Cancers (Basel)       Date:  2021-09-28       Impact factor: 6.575
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.